CRM Fun Quiz #8 - CRM Academy

Sodium-glucose cotransporter 2 (SGLT2) inhibitors only improve outcomes in patients with early-stage CKD

Beta-blockers only improve prognosis in patients with concomitant late-stage CKD and heart failure

The benefits of angiotensin-converting enzyme inhibitors for improving prognosis in heart failure with reduced left ejection fraction are usually lost in patients with CKD

Treatment with a mineralocorticoid receptor antagonist (MRA) may reduce heart failure hospitalizations